{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:43:10Z","timestamp":1777513390860,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Since the advent of biologic therapies for psoriasis, reports of efficacy in nail psoriasis have appeared in the literature and at international conferences with increasing frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This article aims to review the existing literature on the use of biologics in the treatment of nail psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An extensive literature review was conducted using OVID Medline. Studies examining the efficacy of biologics in the treatment of nail psoriasis were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A literature review revealed few clinical trials specifically concentrating on nail psoriasis; however, nails have been assessed in larger clinical trials for cutaneous psoriasis. A large, multicenter, phase III, double-blind, placebo-controlled study of infliximab administered as a brief induction regimen at weeks 0, 2, and 6 followed by a single infusion every 8 weeks revealed statistically significant mean percent improvement in the Nail Psoriasis Severity Index (NAPSI) score over placebo at both week 10 (26.8% vs \u22127.7%, respectively; p &lt; .001) and week 24 (57.2% vs \u22124.1%, respectively; p &lt; .001). For other biologics, evidence has thus far been largely anecdotal, appearing as either case studies or extracted secondarily from open-label prospective trials in plaque psoriasis or psoriatic arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Infliximab appears to be the most effective treatment for nail psoriasis to date.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2310\/7750.2008.08012","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T15:01:24Z","timestamp":1426086084000},"page":"1-5","source":"Crossref","is-referenced-by-count":16,"title":["Nail Psoriasis and Biologics"],"prefix":"10.1177","volume":"13","author":[{"given":"Kristin","family":"Noiles","sequence":"first","affiliation":[{"name":"From the Michael G. DeGroote School of Medicine and the Faculty of Medicine, McMaster University, Hamilton, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Vender","sequence":"additional","affiliation":[{"name":"From the Michael G. DeGroote School of Medicine and the Faculty of Medicine, McMaster University, Hamilton, ON"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,1,1]]},"reference":[{"key":"bibr1-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.027"},{"key":"bibr2-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1159\/000251595"},{"key":"bibr3-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.042"},{"key":"bibr4-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(18)30876-3"},{"key":"bibr5-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/23.4.246"},{"key":"bibr6-7750.2008.08012","unstructured":"Lavaroni G, Kokelj F, Pauluzzi P, The nails in psoriatic arthritis. Acta Derm Venereol 1994;186 113."},{"key":"bibr7-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh198"},{"key":"bibr8-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1159\/000246274"},{"key":"bibr9-7750.2008.08012","unstructured":"Lamerson C, Stevens G, Sax K. Treatment of nail psoriasis with efalizumab. Presented at the Summer American Academy of Dermatology (AAD) 2006; San Diego."},{"key":"bibr10-7750.2008.08012","unstructured":"van den Bosch F, Reece R, Behrens F, Clinically important nail psoriasis imrpovements are achieved with adalimumab (HUMIRA): results from a large open-label prospective study (STEREO). Presented at the EULAR annual scientific meeting; EULAR 2007: The Annual European Congress of Rheumatology; Barcelona, Spain, 2007."},{"key":"bibr11-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"bibr12-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.07.073"},{"key":"bibr13-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"bibr14-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.09.012"},{"key":"bibr15-7750.2008.08012","unstructured":"de Rie M, Giannetti A, Walker S, Nail psoriasis improves after 12 weeks of etanercept therapy in patients with moderate to severe psoriasis. Presented at the 16th Congress of the European Academy of Dermatology & Venereology; Vienna, Austria. 2007."},{"key":"bibr16-7750.2008.08012","unstructured":"Rich P, Gupta A, Wang A, Etanercept improves nail psoriasis. Presented at the Canadian Dermatology Association 80th Annual Conference; Qu\u00e9bec City; 2005."},{"key":"bibr17-7750.2008.08012","unstructured":"Rich P. Efficacy and safety of efalizumab for nail psoriasis: results of an open-label, multicenter study. Presented at the American Academy of Dermatology annual meeting 2008 February 1\u20135; San Antonio, TX."},{"key":"bibr18-7750.2008.08012","unstructured":"Martins G, Stengel F, Allevato M, Efalizumab improves nail psoriasis symptoms: results from a phase IIIB\/IV clinical trial in patients from Latin American countries with moderate-to-severe plaque psoriasis. Presented at the 21st World Congress of Dermatology; 2007 September 30\u2013October 5; Buenos Aires, Argentina."},{"key":"bibr19-7750.2008.08012","doi-asserted-by":"crossref","unstructured":"Cassety CT, Alexis AF, Shupack JL, Alefacept in the treatment of psoriatic nail disease. Presented at the 62nd annual meeting of the American Academy of Dermatology; 2005 February 6\u201311; Washington, DC.","DOI":"10.1016\/j.jaad.2005.01.101"},{"key":"bibr20-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.101"},{"key":"bibr21-7750.2008.08012","first-page":"339","volume":"5","author":"Parrish CA","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"bibr22-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.12.003"},{"key":"bibr23-7750.2008.08012","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.12.002"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2310\/7750.2008.08012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2310\/7750.2008.08012","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2310\/7750.2008.08012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:48:16Z","timestamp":1777391296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2310\/7750.2008.08012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.2310\/7750.2008.08012"],"URL":"https:\/\/doi.org\/10.2310\/7750.2008.08012","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"value":"1203-4754","type":"print"},{"value":"1615-7109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}